Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with (177)Lu-labeled prostate-specific membrane antigen

OBJECTIVE: Up to 60% of patients with metastatic, castration-resistant prostate cancer (mCRPC) treated with (177)Lu prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) achieves a partial biochemical response with a decrease of > 50% in prostate-specific antigen (PSA) levels. The r...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kai, Schatka, Imke, Rogasch, Julian M. M., Lindquist, Randall L., De Santis, Maria, Erber, Barbara, Radojewski, Piotr, Brenner, Winfried, Amthauer, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902572/
https://www.ncbi.nlm.nih.gov/pubmed/33351172
http://dx.doi.org/10.1007/s12149-020-01567-3

Ejemplares similares

Ejemplares similares